W
WAVEMAN · COMPANY
CL · Colgate Palmolive Co
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

CL

COLGATE PALMOLIVE CO
PHARMA & BIOTECH · PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS · CIK 0000021665
CONGRESS · 1FORM 144 · 5☆ WATCH
INSIDER NET · 180D
-$32.0M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
1
FUNDS ADDED · QTR
925
13F, latest reported quarter
REVENUE GROWTH
+1.4%
XBRL, annual
NET MARGIN
10.5%
CONVERSIONS · 180D
3
codes C/M, not in net · $23.6M priced
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$32.0M over 180 days
-$31.0M over 90 days
below 92% of Pharma & Biotech
CONGRESS
1 member bought in the last year
the lowest in Pharma & Biotech
FUNDS
925 funds added or opened last quarter
more than 99% of Pharma & Biotech
REVENUE
+1.4% year over year
below 51% of Pharma & Biotech
MARGIN
10.5% net margin
more than 81% of Pharma & Biotech
BUYBACKS
$597.0M repurchased, FY to 2026-06-30
more than 88% of Pharma & Biotech
SHORT
2.2% of shares outstanding short · 3.8 days to cover · settled 2026-07-31
below 63% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
Insiders are net sellers: -$32.0M across 5 people in 180 days.
925 funds added or opened positions in the latest 13F quarter, of 2,018 holders.
1 member of Congress reported buying it this year.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN +9.4%
+9.4%12M
-11%-1%+9%+19%2025-092025-102025-122026-032026-052026-072026-09 2026-08-05 · Wallace Noel R. sold $14.9M2026-08-04 · Wallace Noel R. sold $14.8M2026-02-04 · SUTULA STANLEY J III sold $9.2M2026-02-04 · Wallace Noel R. sold $4.3M2026-02-11 · Tsourapas Panagiotis sold $3.3M2026-02-04 · Daniels Jennifer sold $2.1M2026-02-10 · Hazlin John sold $2.0M2026-02-05 · Massey Sally sold $1.5M2026-02-12 · Tsourapas Panagiotis sold $1.5M2026-02-06 · Malcolm Gregory sold $1.2M2026-08-24 · Tsourapas Panagiotis sold $920.5K2026-05-07 · Massey Sally sold $751.6K2026-08-06 · CAHILL JOHN T sold $389.4K2026-05-15 · Malcolm Gregory sold $203.4K2025-11-21 · Massey Sally sold $100.1K2026-08-24 · Tsourapas Panagiotis filed to sell $920.5K2026-08-06 · CAHILL JOHN T filed to sell $389.4K2026-08-05 · Wallace Noel R. filed to sell $14.9M2026-08-04 · CAHILLANE STEVEN A filed to sell $159.6K2026-08-04 · Wallace Noel R. filed to sell $14.8M
INSIDER SELLFORM 144
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
Insiders have filed to sell — before selling.
The record shows a net $32.0M sold by insiders over 180 days, 925 funds added last quarter, 1 Congress member(s) bought in 12 months, $31.2M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, COLGATE PALMOLIVE CO insiders sold a net $32.0M of stock across 109 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
Tsourapas Panagiotis
COO, CD, EMEA, APac, Skin
SELL
2026-08-24
10,000.0
$920.5K
CAHILL JOHN T
Director
SELL
2026-08-06
4,170.0
$389.4K
Wallace Noel R.
Chairman, President & CEO
SELL
2026-08-05
161,021.0
$14.9M
Wallace Noel R.
Chairman, President & CEO
SELL
2026-08-04
161,021.0
$14.8M
Malcolm Gregory
EVP and Controller
SELL
2026-05-15
2,300.0
$203.4K
109 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 104 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
BlackRock, Inc.
69,915,472.0 sh
$6.4B
VANGUARD CAPITAL MANAGEMENT LLC
52,246,333.0 sh
$4.8B
STATE STREET CORP
47,020,966.0 sh
$4.3B
VANGUARD PORTFOLIO MANAGEMENT LLC
24,021,137.0 sh
$2.2B
GEODE CAPITAL MANAGEMENT, LLC
23,144,319.0 sh
$2.1B
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
Planned sales · Form 144
Filed before the sale — intent, not a trade
Tsourapas Panagiotis
FILED 2026-08-24
$920.5K
CAHILL JOHN T
FILED 2026-08-06
$389.4K
Wallace Noel R.
FILED 2026-08-05
$14.9M
CAHILLANE STEVEN A
FILED 2026-08-04
$159.6K
Wallace Noel R.
FILED 2026-08-04
$14.8M
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
DIAMOND HILL LARGE CAP CONCENTRATED ETF
$4.1M POSITION · AS OF 2026-03-31
5.7%
State Street(R) Consumer Staples Select Sector SPDR(R) ETF
$678.7M POSITION · AS OF 2026-03-31
4.4%
PROFUND VP CONSUMER STAPLES
$470.0K POSITION · AS OF 2026-03-31
4.3%
DIAMOND HILL LARGE CAP FUND
$157.5M POSITION · AS OF 2026-03-31
4.0%
Franklin Mutual Beacon Fund
$126.8M POSITION · AS OF 2026-03-31
3.8%
SGI U.S. Large Cap Equity Fund
$7.5M POSITION · AS OF 2026-02-28
3.7%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Clinical pipeline
ClinicalTrials.gov · 66 registered trials, 11 still enrolling or running — a status change here is dated weeks before the press release
1
Phase 1
0 ACTIVE
3
Phase 2
0 ACTIVE
47
Phase 3
7 ACTIVE
6
Phase 4
4 ACTIVE
8
Not applicable
0 ACTIVE
1
Multi-phase
0 ACTIVE
TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED
Executive pay vs shareholder return · Noel Wallace
DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself
FY
CEO TOTAL
ACTUALLY PAID
OTHER NEOs AVG
TSR
PEER TSR
2025
$16.5M
$12.3M
$6.4M
+4%
+12%
2024
$18.2M
$31.7M
$4.9M
+17%
+13%
2023
$17.1M
$19.5M
$4.7M
+0%
+8%
2022
$14.5M
$11.0M
$4.1M
-4%
+13%
2021
$15.5M
$18.0M
$4.1M
+2%
+14%
TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$20.4B$20.1B$19.5B$18.0B
GROSS PROFIT$12.3B$12.2B$11.3B$10.2B
OPERATING INCOME$3.3B$4.3B$4.0B$2.9B
NET INCOME$2.1B$2.9B$2.3B$1.8B
EPS (DILUTED)2.633.512.772.13
OPERATING CASH FLOW$4.2B$4.1B$3.7B$2.6B
CASH$1.3B$1.1B$966.0M$775.0M
LONG-TERM DEBT$6.9B$7.3B$8.2B$8.7B
BUYBACKS$1.2B$1.7B$1.1B$1.3B
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →